JLS

Nuveen Mortgage & Income Fund/MA/

NYSE · CIK 0001472215
$17.59 -0.34%
Vol
Inst. Holders2 funds
Inst. Value$2.7M
Inst. Activity0 buys / 1 sells
Insider Activity1B / 0S
Insider Net $$4.5K
Exchange NYSE·CIK 0001472215·Prev Close $17.65

Recent Activity

Mar 23, 2026 Insider
Virgilio Stephen bought 250 shares
$18.05 ($4.5K)
Inst.
UBS Group AG — TRIM
11,482 shares ($215.5K)
Inst.
WELLS FARGO & COMPANY/MN — ADD
62,472 shares ($1.1M)

Top Institutional Holders

FundValueMove
MORGAN STANLEY$1.8M
WELLS FARGO & COMPANY/MN$911.4KADD

Recent Insider Trades

DateInsiderTypeValue
Mar 23, 2026Virgilio StephenBUY$4.5K
2 institutional holders with $2.7M total value (150,090 shares) as of 2025-Q4. Top holders: MORGAN, WELLS.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1MORGAN STANLEY99,988$1.8M66.6%
2WELLS FARGO & COMPANY/MN50,102$911.4K33.4%ADD +49.7%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
UBS Group AGTRIM18,66911,482-38.5%$215.5K2025-Q1
WELLS FARGO & COMPANY/MNADD41,73262,472+49.7%$1.1M2024-Q4
1 unique insiders with 1 transactions. Net insider value: $4.5K ($4.5K bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Mar 23, 2026Virgilio StephenBUY250$18.05$4.5K

No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
$0.00 $0.00 $0.00 $0.0B
Next FY
$0.00 $0.00 $0.00 $0.0B

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.